Actively Recruiting

Phase Not Applicable
Age: 18Years - 75Years
All Genders
NCT05597488

EUS Guided Portal-systemic Pressure Gradient Measurement to Predict Treatment Response and Outcomes of Varices to Endoscopic Variceal Ligation in Patients With Chronic Hepatitis.

Led by Chinese University of Hong Kong · Updated on 2026-03-20

160

Participants Needed

1

Research Sites

208 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The aim of the current study is to assess if EUS-PPGM could predict the treatment response and outcomes of varices to endoscopic variceal ligation (EVL) in patients with chronic hepatitis. The hypothesis is that a high EUS-PPGM value at 3 months correlates with the presence of varices requiring EVL in patients that have received primary or secondary variceal prophylaxis on 1 year follow-up upper endoscopy.

CONDITIONS

Official Title

EUS Guided Portal-systemic Pressure Gradient Measurement to Predict Treatment Response and Outcomes of Varices to Endoscopic Variceal Ligation in Patients With Chronic Hepatitis.

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age between 18 to 75 years old
  • Provided informed consent
  • Diagnosed with chronic hepatitis-induced cirrhosis
  • Have esophageal varices and have received endoscopic variceal ligation (EVL) either as primary prophylaxis during variceal surveillance or as secondary prophylaxis after active variceal bleeding
  • Or have bleeding gastric varices treated with endoscopic cyanoacrylate injection
Not Eligible

You will not qualify if you...

  • Medical Child-Pugh Class C
  • Uncorrected platelet count below 50,000
  • INR greater than 1.5 (natural)
  • History or current hepatic encephalopathy
  • Current or history of hepatocellular carcinoma
  • Main portal vein thrombosis
  • Anatomical alterations of hepatic vasculature preventing access to portal or hepatic veins
  • History of spontaneous bacterial peritonitis within the previous three months
  • Portopulmonary hypertension
  • Cardiac decompensation
  • Presence of ascites blocking the needle path between gastrointestinal tract and liver
  • Presence of gastric or duodenal ulcers, Dieulafoy's lesion, or cancers

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Chinese University of Hong Kong

Hong Kong, Hong Kong, China

Actively Recruiting

Loading map...

Research Team

A

Anthony Teoh

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

DIAGNOSTIC

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here